Jim Cramer Analyzes Johnson & Johnson (JNJ) After Surgical Robotics Milestone

Jim Cramer Analyzes Johnson & Johnson (JNJ) After Surgical Robotics Milestone

Syeda Seirut Javed

Mon, August 3, 2026 at 7:33 PM GMT+3 5 min read

• JNJ -1.41%

Jim Cramer celebrated a dramatic pivot in market sentiment surrounding Johnson & Johnson (NYSE:JNJ) during Mad Money's July 23 episode. After days of urging investors to accumulate the stock following a strong earnings report that Wall Street initially dismissed, Cramer highlighted the FDA approval of JNJ's OTTAVA Robotic Surgical System as the catalyst that finally forced investors to recognize the healthcare titan as a high-tech innovator:

I've been pounding the table on Johnson & Johnson for days now. I thought the quarter was excellent. Nobody agreed with me. The stock got hammered. I've been screaming about how terrific its technology is, saying perhaps it's okay to diversify away from disc drives into JNJ. Nobody seemed to care. Then today we found out that J&J got a green light from the FDA for its OTTAVA Robotic Surgical System. Next thing you know, the stock's going bonkers. Investors realize that J&J, wow, they're a technology company. I say, "Duh, no kidding." But the market's shocked. Look out, J&J is tech. Although it won't matter for a few years.

The OTTAVA Catalyst

On July 22, 2026, Johnson & Johnson announced that the U.S. FDA granted De Novo marketing authorization for its OTTAVA Robotic Surgical System. It is a major milestone as the world's first table-integrated soft-tissue robotic platform. The authorization covers a wide range of general upper-abdominal procedures, including gastric bypass, sleeve gastrectomy, appendectomy, gallbladder removal, and hiatal hernia repair. Johnson & Johnson (NYSE:JNJ) plans a targeted commercial rollout with select U.S. hospital partners to ensure early adoption success while simultaneously pursuing international approvals and conducting ongoing U.S. clinical trials for additional procedures like inguinal hernia repair.

The "Permit Stock" Context: Why Cramer Pounded the Table

This sudden surge validates the broader strategy Cramer laid out on July 6, when he explained why high-quality defensive stocks like JNJ are essential for protecting capital when high-flying market sectors stumble:

Now, you can make good money for a while if you go all in on what's hot, but I never do it because I know it'll eventually blow up in your face… That's why we run a diversified fund for the Investing Club. When you're diversified, at any given moment, you're going to own some losers, though, or at least some stocks that aren't working. These stocks will lag while the data center roars, but they preserve your sanity when you get a tsunami-like sell-off in the hottest stocks out there. Well, the tsunami of data center selling is here, and today's the day when I'm kind of patting myself on the back for keeping the Charitable Trust diversified, not going all in on the data center complex. Today's the day when we're grateful for our Johnson & Johnson position. Great new drug profits. Triple-A balance sheet, better than the United States… See, the lesson's clear, people. The P&Gs and the J&Js in your portfolio allow you to safely own the techs. They're kind of like permits. But if you don't take something off the table of the techs when you're up big, I think you're going to live to regret it.

In Cramer's view, holding JNJ acts as a portfolio "permit" that gives investors clearance to hold aggressive tech growth without exposing their entire balance sheet to sudden market pullbacks.

Stock market data. Photo by Burak The Weekender on Pexels

Surgical Robotics Showdown: JNJ's OTTAVA vs. MedTech Competitors

In the surgical robotics arena, Johnson & Johnson's (NYSE:JNJ) OTTAVA system places the company in direct competition with established industry leaders. Robotic surgery pioneer Intuitive Surgical, Inc. (NASDAQ:ISRG) currently dominates the space with its flagship da Vinci platform, commanding a premium forward earnings multiple near 32 times due to high-margin recurring instrument sales. Meanwhile, medtech peers like Medtronic plc (NYSE:MDT), with its Hugo system, and Stryker Corporation (NYSE:SYK), with its Mako platform, continue to expand their specialized footprints. Johnson & Johnson's (NYSE:JNJ) entry into soft-tissue robotics allows it to use its global hospital network and surgeon relationships. It positions the company to capture long-term market share from peers while trading at a far more conservative valuation multiple.

Big Money Stance & Minimal Short Exposure

Institutional holders maintain a massive presence in Johnson & Johnson (NYSE:JNJ), with fund holdings accounting for roughly 77% of total shares outstanding. Insider Monkey's data shows a significant change in hedge fund sentiment between Q4 2025 and Q1 2026. In Q1, a total of 113 hedge funds held positions in the stock compared to 104 in the prior quarter. Fisher Asset Management held the most prominent stake in the company with 9.26 million shares after increasing its position by 5% sequentially.

On the short side, exchange data reflects a very small bearish sentiment, with JNJ's short interest sitting at 1.14%. That minimal short exposure demonstrates how hesitant traders are to bet against the healthcare giant, especially as new technological milestones begin to unfold.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: Jim Cramer Draws the Line on NVIDIA in China: Why National Security Comes First and Jim Cramer Defends His Dell Stance as Investors Complain About Missing Out.

Disclosure: None. Follow Insider Monkey on Google News.